Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 6Carcinoma, Renal Cell 4Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1

Interventions

Cyclophosphamide 60Vincristine 57Doxorubicin 54Rituximab 48Prednisone 44Etoposide 35Radiotherapy 34Cytarabine 26Filgrastim 22Methotrexate 21Bleomycin 21Dexamethasone 18Peripheral Blood Stem Cell Transplantation 14Carmustine 14Vinblastine 13Prednisolone 13VAP-cyclo protocol 12Melphalan 12Mitoxantrone 11Mercaptopurine 10Leucovorin 10Dacarbazine 9Ifosfamide 8Granulocyte Colony-Stimulating Factor 8Procarbazine 7Methylprednisolone 7Lenalidomide 7Gemcitabine 7Daunorubicin 7Cisplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma × Interferon alpha-2 × Clear all
NCT01609010 2014-09-08

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Hoffmann-La Roche

Phase 3 Completed
313 enrolled 15 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡